Table 1 Characteristics of the participants at baseline.

	Total (n = 54)	Liraglutide (n = 31)	Placebo (n = 23)	P value
Sex (woman)	7 (13.0%)	2 (6.5%)	5 (21.7%)	0.12
Age (years)	66.8 (8.4)	66.7 (9.0)	66.8 (7.7)	0.96
Body mass index (kg/m²)	30.2 (4.9)	30.5 (5.3)	29.7 (4.3)	0.58
Type 2 diabetes
Known duration in years	11.2 [5.2–19.8]	10.9 [4.7–19.8]	11.4 [5.2–21.3]	0.96
HbA_1c (mmol/mol)	57.4 (9.7)	56.9 (8.9)	57.9 (10.8)	0.72
Kidney function
Estimated glomerular filtration rate (mL/min/1.73m²)	84.0 (17.6)	82.5 (19.3)	86.1 (15.1)	0.46
Urinary albumin creatinine rate (mg/g)	5.5 [4.5–15.5]	5.5 [4.5–15.5]	5.5 [4.0–16.0]	0.32
Cardiovascular risk factors
Systolic blood pressure (mm Hg)	134 (16)	134 (16)	135 (17)	0.72
LDL cholesterol (mmol/L)	2.3 (0.68)	2.2 (0.67)	2.4 (0.71)	0.38
Current smoker	9 (16.7%)	7 (22.6%)	2 (8.7%)	0.27
HsCRP (mg/L)	2.3 [0.97–4.7]	1.7 [1.0–4.9]	2.7 [0.9–4.7]	0.33
History of cardiovascular disease^a	11 (20.4%)	7 (22.6%)	4 (17.4%)	0.74
Glucose lowering medication
Insulin use	19 (35.2%)	12 (38.7%)	7 (30.4%)	0.58
SGLT2 inhibitors	10 (18.5%)	4 (12.9%)	6 (26.1%)	0.29
Cardiovascular medication
Aspirin treatment	19 (35.2%)	9 (29.0%)	10 (43.5%)	0.27
Lipid-lowering treatment	48 (88.9%)	29 (93.5%)	19 (82.6%)	0.38

Data are n (%), mean (SD) or median [IQR]. Differences in baseline characteristics between the liraglutide and the placebo group were tested using un-paired t-test and the χ² test.
hsCRP high sensitivity C reactive protein, SGLT2 sodium glucose transporter 2.
^aA history of cardiovascular atherosclerotic disease was defined as a history of acute myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, peripheral arterial thrombosis, claudication and/or nitroglycerin requiring angina pectoris.

Quick links

Search